Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective-Reference-Cited by-同舟云学术

Nonclinical safety assessment of epigenetic modulatory drugs: Current status and industry perspective

Published:2020-11 Issue: Volume:117 Page:104746
ISSN:0273-2300
Container-title:Regulatory Toxicology and Pharmacology
language:en
Short-container-title:Regulatory Toxicology and Pharmacology

Author:

Reynolds Vincent L.,Butler Paul,Abernathy Matthew M.,Aschenbrenner Laura,Best Derek D.,Blank Jim,Crosby Meredith,Custer Laura,Escobar Patricia A.,Kolaja Kyle,Moggs Jonathan,Shuey Dana,Snyder Chelsea,Van Vleet Terry,Zhou Junguo,Hart Timothy K.

Funder

Pfizer

Publisher

Elsevier BV

Subject

Toxicology,General Medicine

Reference54 articles.

1. Chromatin replication and histone dynamics;Alabert;Adv. Exp. Med. Biol.,2017

2. Epigenetic regulation of immune checkpoints: another target for cancer immnotherapy?;Ali;Immunotherapy,2017

3. The molecular hallmarks of epigenetic control;Allis;Nat. Rev. Genet.,2016

4. Epigenetic applications in adverse outcome pathways and environmental risk evaluation;Angrish;Environ. Health Perspect.,2018

5. Epigenetic protein families: a new frontier for drug discovery;Arrowsmith;Nat. Rev. Drug Discov.,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unaltered hepatic wound healing response in male rats with ancestral liver injury;Nature Communications;2023-10-10

2. Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels;Clinical Pharmacology & Therapeutics;2022-05-05

3. Regulatory Issues for Peptide Drugs;Peptide Therapeutics;2022